ReviewAnnals of medicine2026
The regulatory roles of non-coding RNAs in aerobic glycolysis and therapeutic potential in pancreatic ductal adenocarcinoma.
Review in Annals of medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy with a five-year survival rate below 10%, largely due to late diagnosis and rapid metastasis. PDAC cells exhibit profound metabolic reprogramming, particularly enhanced aerobic glycolysis. Non-coding RNAs (ncRNAs), including microRNAs (miRNAs), long non-coding RNAs (lncRNAs) and circular RNAs (circRNAs), have emerged as key regulators of glycolysis in PDAC, although their integrated roles and clinical relevance remain incompletely understood. MAIN
findingsMiRNAs regulate glycolytic flux by targeting key enzymes and signaling pathways, thereby modulating glucose uptake and lactate production. LncRNAs promote glycolysis through pathways such as PI3K/AKT/mTOR, Wnt/β-catenin and p53, or by acting as competing endogenous RNAs. CircRNAs function as miRNA sponges or transcriptional regulators, contributing to metabolic adaptation and chemoresistance. Beyond glycolysis, ncRNAs also influence mitochondrial function, redox balance and tumor microenvironment remodeling. Clinically, several ncRNAs show promise as diagnostic and prognostic biomarkers. Therapeutic strategies targeting ncRNAs, including nano-delivery systems and RNA-based approaches, demonstrate potential for overcoming chemoresistance and enhancing treatment efficacy.
conclusionNcRNAs play central roles in regulating glycolysis and metabolic adaptation in PDAC and represent promising targets for diagnosis and therapy. Further studies are required to validate key regulatory networks and translate these findings into clinical applications.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.